Bengaluru, Karnataka, India, February 2025 – Sandeep Rao has been appointed as the Managing Director & Chief Executive Officer (MD & CEO) of Solara Active Pharma Sciences, effective February 21, 2025. With over 25 years of leadership experience in the pharmaceutical and biotechnology industries, he brings extensive expertise in business strategy, global market expansion, and operational excellence. His appointment marks a strategic step for Solara as the company aims to enhance its global footprint and strengthen operational efficiency.
Before joining Solara Active Pharma Sciences, Sandeep served as the CEO of Tenshi Pharma, where he led governance and operations across API platforms and pharmaceutical assets. Prior to this, he held a key leadership role at Viatris (formerly Mylan) as Vice President & Head of Business Development for Emerging Markets, overseeing business expansion across Latin America, Africa, India, Southeast Asia, and the Middle East.
Earlier in his career, Sandeep spent 16 years at Biocon, where he last served as Senior Vice President & Head of the Insulins Business, managing commercial P&L, insulin manufacturing operations in India and Malaysia, and global product development. His contributions were instrumental in scaling the insulin business, leading the global API exports division, and establishing Biocon’s commercial office in the United States.
Sandeep Rao holds a Master of Business Administration (MBA) from the Indian Institute of Management (IIM) Lucknow and a Master’s degree in Chemistry from the Indian Institute of Technology (IIT) Bombay.
His leadership at Solara Active Pharma Sciences is expected to drive business transformation, enhance global partnerships, and accelerate innovation in active pharmaceutical ingredients (APIs).
About Solara Active Pharma Sciences
Solara Active Pharma Sciences is a leading API manufacturer with a legacy of over three decades. Formed from the expertise of Strides Shasun Ltd. and Sequent Scientific Ltd., the company focuses on value-driven API manufacturing while maintaining strong customer-centric operations. With two state-of-the-art R&D centers and four API manufacturing facilities, Solara continues to pioneer pharmaceutical innovation with globally approved facilities and a dedicated team of over 140 scientists.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
